Provexis plc (PXS) - Total Liabilities

Latest as of September 2025: GBX230.95K GBX ≈ $28.10 USD

Based on the latest financial reports, Provexis plc (PXS) has total liabilities worth GBX230.95K GBX (≈ $28.10 USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore how efficiently does Provexis plc generate cash to assess how effectively this company generates cash.

Provexis plc - Total Liabilities Trend (2004–2025)

This chart illustrates how Provexis plc's total liabilities have evolved over time, based on quarterly financial data. See PXS total equity for net asset value and shareholders' equity analysis.

Provexis plc Competitors by Total Liabilities

The table below lists competitors of Provexis plc ranked by their total liabilities.

Company Country Total Liabilities
Goldplat PLC
LSE:GDP
UK GBX16.02 Million
Crown LNG Holdings Limited Ordinary Shares
NASDAQ:CGBS
USA $16.20 Million
TUT Fitness Group Inc
V:GYM
Canada CA$533.79K
TTA Holdings Ltd
AU:TTA
Australia AU$594.78K
Tongaat
JSE:TON
South Africa ZAC7.30 Billion
Sino-German United AG
F:SGU
Germany €1.00 Million
Cirata plc
LSE:CRTA
UK GBX4.94 Million
iomart Group plc
LSE:IOM
UK GBX183.30 Million

Liability Composition Analysis (2004–2025)

This chart breaks down Provexis plc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Provexis plc stock valuation.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 3.65 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 0.20 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.27 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Provexis plc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Provexis plc (2004–2025)

The table below shows the annual total liabilities of Provexis plc from 2004 to 2025.

Year Total Liabilities Change
2025-03-31 GBX248.21K
≈ $30.20
-19.27%
2024-03-31 GBX307.45K
≈ $37.41
+63.24%
2023-03-31 GBX188.34K
≈ $22.92
+19.27%
2022-03-31 GBX157.91K
≈ $19.21
+4.80%
2021-03-31 GBX150.68K
≈ $18.33
+0.40%
2020-03-31 GBX150.08K
≈ $18.26
+21.87%
2019-03-31 GBX123.14K
≈ $14.98
+37.77%
2018-03-31 GBX89.38K
≈ $10.88
-32.95%
2017-03-31 GBX133.31K
≈ $16.22
+17.20%
2016-03-31 GBX113.75K
≈ $13.84
-0.29%
2015-03-31 GBX114.08K
≈ $13.88
+5.42%
2014-03-31 GBX108.21K
≈ $13.17
-95.61%
2013-03-31 GBX2.47 Million
≈ $299.92
+16.49%
2012-03-31 GBX2.12 Million
≈ $257.46
+275.18%
2011-03-31 GBX564.00K
≈ $68.62
+91.19%
2010-03-31 GBX295.00K
≈ $35.89
+26.07%
2009-03-31 GBX234.00K
≈ $28.47
-35.18%
2008-03-31 GBX361.00K
≈ $43.92
-56.97%
2007-03-31 GBX839.00K
≈ $102.08
+3.97%
2006-03-31 GBX807.00K
≈ $98.19
-14.42%
2005-03-31 GBX943.00K
≈ $114.74
+338.60%
2004-03-31 GBX215.00K
≈ $26.16
--

About Provexis plc

LSE:PXS UK Drug Manufacturers - Specialty & Generic
Market Cap
$291.14K
GBX2.39 Billion GBX
Market Cap Rank
#30726 Global
#978 in UK
Share Price
GBX1.02
Change (1 day)
+0.00%
52-Week Range
GBX0.50 - GBX1.51
All Time High
GBX1.51
About

Provexis plc, together with its subsidiaries, develops, licenses, and sells functional foods, medical foods, and dietary supplements worldwide. The company offers syrup and powder versions of Fruitflow, a tomato extract that reduces the propensity for aberrant blood clotting typically associated with cardiovascular diseases, such as heart attack and stroke used in various foods, beverages, and di… Read more